Abstract
Mass cytometry has emerged as a new state-of-the-art technology that enables in-depth characterization of cellular populations and functions at a single cell resolution. We describe the application of this technology to deeply phenotype the blood and bone marrow components of multiple myeloma patients in a clinical setting. This technology allows for simultaneous quantification of more than 40 markers, overcoming the challenges of traditional fluorescence-based flow cytometry.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Change history
07 February 2019
In Chapter 4, the author’s name Homer Adams III has been modified to Adams HC 3rd, as requested by him.
References
Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK (2012) A deep profiler’s guide to cytometry. Trends Immunol 33(7):323–332. https://doi.org/10.1016/j.it.2012.02.010
Spitzer MH, Nolan GP (2016) Mass Cytometry: single cells, many features. Cell 165(4):780–791. https://doi.org/10.1016/j.cell.2016.04.019
Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373(13):1207–1219. https://doi.org/10.1056/NEJMoa1506348
Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387(10027):1551–1560. https://doi.org/10.1016/S0140-6736(15)01120-4
Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG (2016) Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood 128(14):1821–1828. https://doi.org/10.1182/blood-2016-07-726729
Adams H, Stevenaert F, Krejcik J, Van der Borght K, Casneuf T, Smets T, Bald J, Abraham Y, Ceulemans H, Vanhoof G, Ahmadi T, Usmani SZ, Plesner T, Lonial S, van Kessel-Welmers B, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK (2016) High-parameter mass cytometry (CyTOF) evaluation of relapsed/refractory multiple myeloma (MM) Pts (Pts) treated with daratumumab supports immune modulation as a novel mechanism of action. Blood 128(22):4521
Qiu P, Simonds EF, Bendall SC, Gibbs KD Jr, Bruggner RV, Linderman MD, Sachs K, Nolan GP, Plevritis SK (2011) Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol 29(10):886–891. https://doi.org/10.1038/nbt.1991
Acknowledgments
The authors would like to thank Christoph Heuck for his suggestions and critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Smets, T., Stevenaert, F., Adams, H., Vanhoof, G. (2018). Deep Profiling of the Immune System of Multiple Myeloma Patients Using Cytometry by Time-of-Flight (CyTOF). In: Heuck, C., Weinhold, N. (eds) Multiple Myeloma. Methods in Molecular Biology, vol 1792. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-7865-6_4
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7865-6_4
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-7864-9
Online ISBN: 978-1-4939-7865-6
eBook Packages: Springer Protocols